Psychiatry & Neurology Doctors in Shawnee, KS Accepting Medicare

3 Psychiatry & Neurology doctors found. Showing 1 - 3

John Henry Wisner Jr., M.D. Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 6522 Hedge Lane Ter, #201, Shawnee, KS 66226 Phone: 913-972-5730

Jo Jeanne Callaway, MD Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 5400 Lackman Road, Shawnee, KS 66217 Phone: 913-631-4625

Dr. Syed Mohiuddin, M.D. Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 6440 Nieman Rd, Shawnee, KS 66203 Phone: 913-826-4200    Fax: 913-826-1589

News Archive

Research highlights association of western diet with Alzheimer's disease

Recent research has established associations between certain environmental factors, including eating a western diet and being sedentary, with an increased susceptibility to Alzheimer's disease. In fact, it is estimated that a combination of diet and inactivity contributes to as many as 25% of Alzheimer's cases. Nonetheless, little is known about the exact disease mechanisms and how or why this increasingly common middle-age lifestyle can play such a big role in subsequent cognitive function.

Phonak expands its latest-generation Belong platform with Phonak Naída B, Phonak Sky B hearing aids

Phonak, the leading global innovator for hearing instruments and wireless communication solutions, today announces the extension of its latest-generation Belong platform with Phonak Naída™ B and Phonak Sky™ B hearing aids.

Luna Innovations posts year-on-year decline in second-quarter 2009 revenues

Luna Innovations Incorporated (NASDAQ:LUNA), a company focusing on sensing & instrumentation and pharmaceutical nanomedicines, today announced its financial results for the quarter ended June 30, 2009.

TeleTracking releases Capacity Management Suite system version 2.3

TeleTracking Technologies today announced release of its Capacity Management Suite system version 2.3, which allows users to control core patient flow automation functions from an Apple iPad, streamline sign-on protocol for faster login, and speed responses to unexpected spills.

Cell Therapeutics initiates Phase 3 clinical trial to evaluate pacritinib in patients with myelofibrosis

Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the initiation of a Phase 3 clinical trial, known as PERSIST-2, which will evaluate pacritinib, a novel, investigational JAK2/FLT3 inhibitor, in patients with myelofibrosis whose platelet counts are less than or equal to 100,000 per microliter (uL).

Read more Medical News

› Verified 9 days ago